From Financial Modeling Prep: 2024-10-02 05:46:32

Palatin Technologies reported positive developments in its pipeline during the recent earnings call, focusing on the success of Bremelanotide in treating HSDD in women and expanding its indications. The company also highlighted progress in ophthalmology and autoimmune disorder treatments, targeting pivotal milestones in 2024.

To enhance its financial health for FY 2024, Palatin is strategically selling non-core assets to streamline operations and strengthen its balance sheet. The proceeds from these sales will support clinical trials and product launches next year. Analysts and investors can access detailed financial insights through the Full Financials API from Financial Modeling Prep.



Read more at Financial Modeling Prep:: Palatin Technologies Earnings Call: Pipeline Progr…